Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8461333 | VIIV HLTHCARE | Salts of prodrugs of piperazine and substituted piperidine antiviral agents |
Feb, 2025
(10 months from now) | |
US7745625 | VIIV HLTHCARE | Prodrugs of piperazine and substituted piperidine antiviral agents |
Nov, 2027
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8168615 | VIIV HLTHCARE | Prodrugs of piperazine and substituted piperidine antiviral agents |
Feb, 2025
(10 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 02, 2025 |
NCE-1 date: 02 July, 2024
Market Authorisation Date: 02 July, 2020
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL